Citius Pharmaceuticals
- Company typePublic
- Founded2010
- HeadquartersCranford, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Citius Pharmaceuticals firmographics
Firmographics- Name
- Citius Pharmaceuticals
- Legal name
- Citius Pharmaceuticals, Inc.
- Website
- https://citiuspharma.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Citius Pharmaceuticals industry classification
Industry- Product category
- Specialty Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industry
- Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
Keywords
Where Citius Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Cranford
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Citius Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations
Revenue model
- LYMPHIR Product Sales: Revenue generated from commercial sales of LYMPHIR (denileukin diftitox-cxdl) following FDA approval and December 2025 U.S. launch. The product achieved $5.6 million in net revenue for H1 FY2026 with approximately 80% gross margins, representing the company's first revenue-generating period.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Citius Pharmaceuticals product offering
Product offeringCore offering
Citius Pharmaceuticals is a late-stage biopharmaceutical company that develops, manufactures, and commercializes first-in-class critical care therapeutics. Its lead product LYMPHIR (denileukin diftitox-cxdl) is an FDA-approved engineered IL-2-diphtheria toxin fusion protein for relapsed/refractory cutaneous T-cell lymphoma commercially launched in the U.S. in December 2025. The pipeline includes Mino-Lok antibiotic lock therapy for catheter salvage, Halo-Lido topical hemorrhoid therapy, and an i-MSC stem cell platform for acute respiratory distress syndrome.
Product overview
Citius Pharmaceuticals is a late-stage biopharmaceutical company with a diversified pipeline of critical care products. The company's portfolio includes LYMPHIR (denileukin diftitox-cxdl), an FDA-approved targeted immunotherapy for cutaneous T-cell lymphoma; Mino-Lok, an antibiotic lock solution for salvaging infected catheters; Halo-Lido, a topical hemorrhoid treatment in late-stage development; and a stem cell platform using engineered i-MSCs for respiratory conditions. The company operates through its majority-owned subsidiary Citius Oncology, which commercializes LYMPHIR.
Differentiator
Problem solved
Functional benefit
Brands
- LYMPHIR: FDA-approved targeted immune therapy (denileukin diftitox-cxdl) for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL).
- Mino-Lok
- Halo-Lido
- Stem Cell Platform (i-MSCs)
Products and services
- LYMPHIR (denileukin diftitox-cxdl) FDA-approved engineered IL-2-diphtheria toxin fusion protein (immunotoxin) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL), including mycosis fungoides and Sézary Syndrome, after at least one prior systemic therapy. The drug targets both malignant T-cells and immunosuppressive regulatory T-cells (Tregs). Sold to oncology specialty centers, academic cancer centers, and community infusion centers.
- Mino-Lok Investigational antibiotic lock solution combining minocycline, edetate (disodium EDTA), and ethyl alcohol for salvaging infected central venous catheters in patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs). Demonstrated 100% catheter salvage rate in Phase 2b trial. Targeted to hospitals, oncology treatment centers, and dialysis centers serving cancer and hemodialysis patients.
- Halo-Lido (CITI-002) Proprietary topical prescription formulation combining halobetasol (high-potency corticosteroid) and lidocaine (anesthetic) for symptomatic relief of hemorrhoids. If approved, would be the first FDA-approved prescription product for hemorrhoids in the United States. Targeted to primary care physicians, gastroenterologists, proctologists, and colorectal surgeons.
- i-MSC Stem Cell Platform Next-generation engineered induced mesenchymal stem cells (i-MSCs) derived from induced pluripotent stem cells (iPSCs) under cGMP using a patented synthetic, non-immunogenic, non-viral mRNA reprogramming technique. Targeted to treatment of acute respiratory distress syndrome (ARDS) and other acute inflammatory respiratory disorders. Developed through majority-owned subsidiary NoveCite Inc.
Quantifiable outcome
- 24% objective response rate (ORR) in heavily pre-treated gynecologic cancer patients with LYMPHIR + pembrolizumab combination, including 33% ORR in endometrial cancer patients previously treated with checkpoint inhibitors
- +4 more outcomes
Companies that use Citius Pharmaceuticals
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Citius Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Citius Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core.
- University of Pittsburgh Medical Center (UPMC)coreInvestigator-initiated Phase 1 trial evaluating LYMPHIR in combination with pembrolizumab in patients with recurrent or refractory gynecologic malignancies. Study demonstrated 24% overall response rate and 33% ORR in endometrial cancer patients previously treated with checkpoint inhibitors.
- University of Minnesota and City of HopecoreInvestigator-initiated Phase 1 trial evaluating LYMPHIR administered prior to CAR-T therapy in high-risk relapsed/refractory diffuse large B-cell lymphoma patients. Study demonstrated 86% overall response rate with 57% complete responses and strong one-year survival rates.
- UnipharcoreEuropean distribution agreement for LYMPHIR with Uniphar, a leading international healthcare services company. LYMPHIR being made available through Named Patient Programs across 19 markets including Southern Europe, Middle East, and additional European territories. Initial shipment completed April 29, 2026.
- McKesson CorporationcoreU.S. distribution agreement with McKesson for LYMPHIR commercial launch. This alliance completed Citius Oncology's distribution network with all three largest U.S. pharmaceutical distributors to ensure broad access to the therapy.
- EVERSANAcoreExclusive agreement with EVERSANA to support U.S. commercialization of LYMPHIR for Q4 2025 launch. EVERSANA provides integrated services for market entry and launch readiness including commercial analytics, market access, and distribution support.
- Eisai Co. Ltd.coreCitius acquired exclusive license to develop and commercialize late-stage cancer immunotherapy (LYMPHIR) for which Dr. Reddy's Laboratories SA (in association with Eisai) was completing a fully-enrolled Phase 3 pivotal trial in persistent or recurrent CTCL. Eisai retained responsibility for completing the Pivotal trial and associated CMC activities through BLA filing with FDA. LYMPHIR approved by FDA in August 2024.
- Brooklyn ImmunoTherapeutics (formerly Novellus Therapeutics)corePartnered to create NoveCite Inc., a majority-owned subsidiary of Citius focused on developing, manufacturing, and commercializing a unique induced mesenchymal stem cell (i-MSC) platform for treatment of acute respiratory distress syndrome (ARDS), including COVID-19 related cases. Novellus acquired by Brooklyn ImmunoTherapeutics in July 2021.
- MD Anderson Cancer CentercoreLicensed worldwide rights to Mino-Lok, the first and only product in development to salvage infected Central Venous Catheters. Also acquired worldwide license for Mino-Wrap in January 2019, potentially the first product for prevention of infections associated with post-mastectomy implants. Both products were developed by clinicians and technologists at MD Anderson.
Scale indicators14 records
Recent moves1 record
Citius Pharmaceuticals competitors and assessment
Company assessmentEmerging players
- Athersys: Athersys developed MultiStem cell therapy for ARDS and stroke, a partial overlap with Citius's i-MSC platform. Both are early-stage cell therapy companies pursuing allogeneic stem cell approaches for critical care indications with similar regulatory and manufacturing risk profiles.
- Fortress Biotech: Fortress Biotech is a small specialty pharma holding company developing and commercializing multiple products across oncology, infectious disease, and rare diseases. Its diversified pipeline and partnership-driven commercialization model parallels Citius's multi-asset strategy.
Broad incumbents
- Spectrum Pharmaceuticals: Spectrum is a specialty oncology pharmaceutical company commercializing hematology and oncology products through specialty distribution. It shares Citius's profile of branded specialty injectable biologics targeting smaller oncology indications with hospital-channel distribution.
- Eagle Pharmaceuticals: Eagle Pharmaceuticals is a specialty injectable pharmaceutical company focused on oncology and critical care, with a comparable product profile of branded hospital-administered therapies and similar small-cap public profile. Like Citius, Eagle commercializes differentiated specialty products through hospital and specialty pharmacy channels.
Direct peers
- Mesoblast: Mesoblast is a cell therapy company developing mesenchymal stem cell therapies for inflammatory conditions including ARDS, directly comparable to Citius's i-MSC platform. Both companies pursue allogeneic stem cell approaches for respiratory and inflammatory critical care indications.
- Verastem Oncology: Verastem is a small-cap oncology-focused biopharma commercializing targeted therapies for hematologic malignancies and solid tumors. It is a direct peer in micro-cap oncology specialty pharma, with similar pipeline breadth and commercialization challenges.
- Soligenix: Soligenix is a late-stage specialty biopharma developing products in oncology and infectious disease with a similar small-cap, multi-asset profile. Its diversified pipeline of critical care products mirrors Citius's structure across multiple specialty therapeutic areas.
- Innate Pharma: Innate Pharma develops antibody-based immunotherapies for cancer including lacutamab for CTCL, a direct competitor to LYMPHIR in the relapsed/refractory CTCL indication. Innate's CTCL focus and immunology-oncology platform make it a directly comparable peer for Citius's lead asset.
- Acrotech Biopharma: Acrotech is a specialty oncology company developing and commercializing differentiated therapeutics for rare and difficult-to-treat cancers. Its focus on niche oncology indications and specialty distribution channels is closely aligned with Citius's LYMPHIR commercial model.
- Tarsus Pharmaceuticals: Tarsus is a specialty pharma that recently launched its first FDA-approved product (Xdemvy) targeting a niche indication, sharing Citius's profile of a small-cap specialty pharma with one recently approved product and a broader specialty pipeline.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Citius Pharmaceuticals social profiles
Digital presenceCitius Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Citius Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles14 records
Citius Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries2 records
Citius Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds20 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Citius Pharmaceuticals M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Citius Pharmaceuticals
What does Citius Pharmaceuticals do?
Citius Pharmaceuticals is a late-stage biopharmaceutical company that develops, manufactures, and commercializes first-in-class critical care therapeutics. Its lead product LYMPHIR (denileukin diftitox-cxdl) is an FDA-approved engineered IL-2-diphtheria toxin fusion protein for relapsed/refractory cutaneous T-cell lymphoma commercially launched in the U.S. in December 2025. The pipeline includes Mino-Lok antibiotic lock therapy for catheter salvage, Halo-Lido topical hemorrhoid therapy, and an i-MSC stem cell platform for acute respiratory distress syndrome.
Is Citius Pharmaceuticals a public or private company?
Citius Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Citius Pharmaceuticals founded?
Citius Pharmaceuticals was founded in 2010. It employs 11 to 50 people.
Where is Citius Pharmaceuticals based?
Citius Pharmaceuticals is headquartered in Cranford, United States, in the North America region.
How does Citius Pharmaceuticals make money?
One revenue line is on record: LYMPHIR Product Sales.
Who are Citius Pharmaceuticals's main competitors?
Emerging players on record are Athersys and Fortress Biotech. Broad incumbents are Spectrum Pharmaceuticals and Eagle Pharmaceuticals. Direct peers are Mesoblast, Verastem Oncology, Soligenix, Innate Pharma, Acrotech Biopharma and Tarsus Pharmaceuticals.
Does Citius Pharmaceuticals have an API?
No public API is recorded for Citius Pharmaceuticals.
What industry is Citius Pharmaceuticals in?
Citius Pharmaceuticals's product category is Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 325412 and its SIC code is 2834.